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Cambridge, Massachusetts 02138 that is ªopen,º thus favoring the dissociation and associ-
ation of peptides (Ghosh et al., 1995; Denzin et al., 1996;²Department of Molecular Immunology
Merck Research Laboratories Sanderson et al., 1996; Vogt et al., 1996; Weber et al.,
1996; Kropshofer et al., 1997). The crystal structure ofRahway, New Jersey 07065
DM, reported here, reveals a class II±like molecule with-
out a peptide-binding groove but containing a curious
polar, possibly vestigial, pocket and a tryptophan-richSummary
lateral surface that is a candidate for binding the inhibitor
HLA-DO (Liljedahl et al., 1996; Denzin et al., 1997; vanThe three-dimensional structure of the soluble ecto-
Ham et al., 1997) and if bound to substrates like HLA-domain of HLA-DM has been determined to 2.5 AÊ reso-
DR might distort the peptide-binding site.lution by X-ray crystallography. HLA-DM has bothpep-
tide exchange activity and acts as a chaperone to
Resultspeptide-free class II MHC molecules. As predicted,
the structure is similar to that of classical class II MHC
Structure Determinationmolecules except that the peptide-binding site is al-
HLA-DM with peptide epitope tags (ªFLAGº on a andtered to an almost fully closed groove. An unusual
ªKT3º on b) replacing the transmembrane and cyto-cavity is found at the center of the region that binds
plasmic regions of the a and b polypeptides was pro-peptides in class II MHC molecules, and a tryptophan-
duced in Drosophila S2 cells and purified as previouslyrich lateral surface is identified that is a candidate both
described (Sloan et al., 1995) (see Experimental Proce-for binding to HLA-DR, to effect catalysis, and to HLA-
dures). Crystals were grown near the pH optimum (pHDO, an inhibitor.
5.4) of the enzyme (see Experimental Procedures), and
the crystalline protein was shown by a native gel-shiftIntroduction
assay to enhance peptide loading of both empty and
CLIP-containing, soluble HLA-DR1 and HLA-DR4 (Ex-After biosynthesis into the endoplasmic reticulum, class
perimental Procedures; data not shown). The structureII MHC molecules bind to the invariant chain protein (Ii)
was determined by molecular replacement, with HLA-and are escorted to an endosomal compartment. There
DR1 (Stern et al., 1994) as a search model, and refinedproteolysis removes Ii and HLA-DM catalyses exchange
to 2.5 AÊ resolution (Rfree5 .256, Rwork5 .194) (Experimentalof the contents of the MHC-binding site, a peptide rem-
Procedures). The final model contains a chain residuesnant of Ii named CLIP, for antigenic peptides (Riberdy
13-199 and b 3-192, 198 solvent molecules, and threeet al., 1992; Sette et al., 1992; Cresswell, 1994, 1996;
saccharides attached at Asn a15.Denzin and Cresswell, 1995; Sherman et al., 1995; Sloan
et al., 1995; Wolf and Ploegh, 1995). Leaving DM behind
in endosomes, peptide/MHC complexes move to the Three-Dimensional Structure of HLA-DM
cell surface with the peptides kinetically trapped (disso- Compared to HLA-DR
ciation t1/2 . 50 hr), a requirement as extracellular anti- The overall fold and domain organization of DM is similar
genic peptide concentrations are vanishingly small. Mu- to that of classical class II MHC molecules (Busch et
tant cells lacking DM express class II molecules on the al., 1998b; Dessen et al., 1997; references therein), as
cell surface loaded with CLIP (Fing et al., 1994; Morris expected from the 28% sequence identity (Cho et al.,
et al., 1994), which occupies the peptide-binding site 1991; Kelly et al., 1991) and from data indicating the
like an antigenic peptide but with nonoptimal anchoring requirement for formation of a homologous disulfide
residues (Ghosh et al., 1995). bond (Busch et al., 1998a) (rmsd 5 2.9 AÊ for 360 Ca
In vitro, tight peptide binding (Watts and McConnell, pairs) (Figure 1A). DM contains twonovel disulfide bonds
1986; Buus et al., 1987, 1988), even to peptide-free, (a 24-79 and b 25-35) (green, Figure 1A) in the region
ªemptyº class II molecules, is very slow (t1/2 5 24 hr) homologous to the peptide-binding site of DR. None
(Stern and Wiley, 1992); DM increases this rate by z104 of the conserved residues identified in DR1 that form
(Weber et al., 1996). It binds to class II molecules, like hydrogen bonds to the main chain atoms of bound pep-
HLA-DR, acting as a chaperone by preventing the aggre- tides are conserved in DM and none of the pockets
gation of empty DR (Stern and Wiley, 1992; Germain identified for binding the side chains of peptides are
and Rinker, 1993), which increases the yield of peptide present (Stern et al., 1994) (albeit, see below). Instead
complexes (Denzin et al., 1996; Sanderson et al., 1996; of forming a peptide-binding groove, the a helices of
the a1 and b1 domains of DM contact each other over
the first and last thirds of their lengths (Figure 1B), like³To whom correspondence should be addressed (e-mail: dcwad
min@crystal.harvard.edu). those of the class I-like, neonatal Fc receptor (FcRn)
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Figure 1. Comparison of the Structures of HLA-DM, HLA-DR1, and FcRn, the Neonatal Fc Receptor
(A) DM (yellow), DR1 (red), disulfide bonds (green). The locations of tryptophans a62 and b120 are labeled with arrows.
(B) Superposition of the a1 and b1 domains of HLA-DM (yellow) and HLA-DR1 (red). (rmsd 5 2.5 AÊ for 160 Ca pairs).
(C) Superposition of the a1 and b1 domains of HLA-DM (yellow) and a1 and a2 domains of FcRn (gray) (rmsd 5 2.4 AÊ for 153 Ca pairs).
(D) Superposition of the a2 and the b2 domains of HLA-DM (yellow) and HLA-DR1 (red) (a2 domain, rmsd 5 1.04 AÊ for 92 Ca pairs; b2 domain,
rmsd 5 2.1 AÊ for 93 Ca pairs).
(Burmeister et al., 1994) (Figure 1C), precluding peptide larger than a vestigial dimple found in the same region
of FcRn (Burmeister et al., 1994) but smaller than thebinding as expected (Busch and Mellins, 1996). There
are some differences in the conformations of several groove and cavity in the class I±like molecule CD1 (Zeng
et al., 1997), which apparently presents lipid and glyco-loops in the a2 and b2 domains of DM relative to DR
(Figure 1D), but most are at crystal contacts that may lipid mycobacterial antigens (Beckman et al., 1994). The
DM pocket is completely unlike the long groove of pock-distort their shapes. The b2 chain in DM, as it passes
from the second b sheet back to the first, also takes ets in a class II molecule (Figure 2C).
a slightly different path than in DR (Figure 1D). These
differences permit the formation of a dimer of DM het- A Central Pocket
erodimers in the crystal, different from that that DR1 At the bottom of this central pocket is a puzzling ar-
can form (see below) (Brown et al., 1993). rangement of a familiar triad, Serine b9, Histidine a20,
and Glutamic acid a35 (or Aspartic acid a68), arranged
like the catalytic triad in serine proteases and esterasesA Closed Groove
Three protuberant kinks in the b1 domain a helix cause (Figure 2A) (Stryer, 1981). But, this triad could not act
as a protease because there is no groove to bind aa zigzag in its course across the domain (dashed line,
Figure 2A). This separates the residues packed between peptide, rather just a dead-end pocket as might form
an acetylesterase (Wei et al., 1995) or binding site forthe two domains into three apparent clusters (inserts in
Figure 2). Two of the clusters, at the two ends of the an amidated carboxylate or acetylated amine (caption
Figure 2B). Importantly, there are nopolar residues form-domains, are nonpolar residues mediating tight packing
(9.5 AÊ helix to helix) between the a helices of the a1 and ing an oxy-anion hole to stabilize a tetrahedral inter-
mediate generated by a serine nucleophilic attack on ab1 domains (Figure 2). The central cluster, by contrast,
is polar, and charged residues (Figure 2A) form a 10 AÊ carbonyl. Thus, the juxtaposition of Ser/His/Glu (Asp),
conserved in all known DM sequences, does not formwide and 10 AÊ deep pocket (Figure 2B). This pocket is
HLA-DM 3-Dimensional Structure
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Figure 2. Helical Packing in HLA-DM
(A) Three segments of the helical region pack
differently. At each end of the domains the
helicescontact eachother with nonpolar resi-
dues; in the middle is a deep pocket of polar
residues. At the bottom of the cavity, both
Glu a35 and Asp a68 are within hydrogen
bonding distance of His a20. The hydroxyl
group of Ser b9 could be rotated to hydrogen
bond directly to His a20 but in the structure
is hydrogen bonded through a water mole-
cule to His a20.
(B) Surface representation of HLA-DM (same
viewpoint as in [A]). Arrowshows central deep
pocket, also shown in detailed dot surface.
(C) Surface representation of HLA-DR1 (with
bound peptide omitted). Peptide side chain
binding pockets between the a helices are
labeled.
a catalytic site. Whether it is a vestige of such a site or DM homologs will have bulky hydrophobic residues pre-
venting peptide binding at either ends and a pocket,whether it can bind some pendant ligand such as a
modified peptide terminus is unknown. possibly vestigial, at its center.
Besides binding to class II MHC molecules, DM binds
intracellularly to HLA-DO, a class II±like heterodimerDetails of the HLA-DM Structure Are Conserved
(Liljedahl et al., 1996; Douek and Altmann, 1997) thatin Other Species
evidence indicates is a pH-dependent, negative regula-Most of the residues that fix the a helices of the a1 and
tor of DM activity (Denzin et al., 1997; van Ham et al.,b1 domains tightly together and much of the pocket
1997; Liljedahl et al., 1998). The a and b chains of theare conserved among human HLA-DM and homologous
inhibitor DO have approximately 60% sequence identitymurine, rabbit, and bovine sequences, while residues
to DR1 (Tonnelle et al., 1985; Trowsdale and Kelly, 1985).that project away from this interface vary and display
One simple model for inhibition by DO would be for bothlimited polymorphism within the mouse H2-M alleles.
DR and DO to compete for the same site on DM.This contrasts with the distribution of conserved and
polymorphic positions in the classical class II MHC mol-
ecules, where amino acid variations inside the groove A Crystal Packing Dimer of DM
DM crystals contain 2-fold symmetric dimers of ab DMpermit each MHC allelic product to bind different pep-
tides. The conservation of sequence suggests that all heterodimers that are probably crystal packing artifacts
Immunity
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Figure 3. Conserved Hydrogen Bonds be-
tween CLIP and HLA-DR3
Dashed lines show hydrogen bonds between
peptide backbone atoms found on all bound
peptides and residues conserved in all class
II molecules, shown for HLA-DR3/CLIP (Ghosh
et al., 1995). Hydrogen bonds made by pep-
tide positions 1, 21, and 22 (numbered
as in Stern et al., 1994) are labeled P1, P-1,
and P-2.
(with a geometryunlike either DR or I-A dimers described peptide side chain/MHC interactions, because those in-
volve polymorphic pockets and allele-specific peptidepreviously (Brown et al., 1993; Jardetzky et al., 1994;
Stern et al., 1994; Ghosh et al., 1995; Fremont et al., anchor residues that are different in different class II/
peptide pairs. The rate enhancement due to DM could1996). They are unlikely to be models for either the inter-
action of DM with DO or with DR (DP and DQ), because result from DM breaking 2 or 3 of the 11 hydrogen bonds
between bound peptide main chain atoms and con-the dimers are held together at the membrane distal
domains only by contacts involving the oligosaccha- served class II residues observed in all class II/peptide
complexes (Stern et al., 1994; Dessen et al., 1997; refer-rides of eacha chain (Asn 15, Figure 1A), and DOlacks an
equivalent oligosaccharide to form a similar interaction; ences therein) (Figure 3).
The three peptide-to-MHC hydrogen bonds nearestfurthermore, DM from cells with N-glycosylation blocked
by tunicamycin is known to catalyze peptide exchange to the peptide N terminus (labeled P-2, P-1, and P1
in Figure 3) are good prospects for disruption by DM(Guerra et al., 1998).
because of their accessibility on class II structures. Two
of them are to an extended strand (Ser a53) of DR thatDiscussion
might be displaced more easily than the binding site
helices, and one (His b81) extends vulnerably out of theThe crystal structure of CLIP (Ii 81±104) bound to HLA-
DR3 showed that this intermediate in the maturation of binding-site groove. The six other conserved hydrogen
bonds are sheltered within the helical walls of the bind-DR had the same conformation as DR complexed with
tightly binding peptides, leading to the proposal that to ing site where their disruption would require more com-
plex distortions of the binding site (Figure 3). The struc-remove CLIP and catalyze peptide exchange, DM must
preferentially bind to a strained, transition-state con- ture of DM reveals one lateral surface that contains two
partially exposed tryptophans (a62 and b120; .50AÊ 2)former of DR that favors dissociation and association
of peptides (Ghosh et al., 1995). A physical association and is a candidate for binding DR (arrows in Figure 1A).
(Fewer aromatic dye molecules bind DM/DR than toof DM with DR after CLIP dissociation has been ob-
served by immune coprecipitation (Denzin et al., 1996; either molecule separately, suggesting that nonpolar
surfaces form the interface [Ullrich et al., 1997].)Sanderson et al., 1996; Kropshofer et al., 1997), sug-
gesting that DM binds tightly to an intermediate, ªopen- This DM surface (front surface in Figure 1A, left in
Figure 3) is homologous to the surface of DR implicatedemptyº conformation of DR, such as would result after
CLIP had been exchanged off. Some of the interactions in DM binding by mutation studies (Mellins et al., 1994;
Guerra et al., 1998) consistent with the possible forma-between the DR molecule and the peptide would be
weakened or broken in this open state, facilitating the tion of a symmetric DM/DR dimer. The addition of an
oligosaccharide at DR a94 (Figure 1A) disrupts DM ex-dissociation or association of peptides.
On the basis of kinetic studies of the DM exchange change activity both in vivo and in vitro (Mellins et al.,
1994; Sloan et al., 1995; Guerra et al., 1998) as well asreaction (Vogt et al., 1996; Weber et al., 1996), Jensen
and colleagues showed that the rate of DM-induced the physical interaction of DM/DR (Denzin et al., 1996;
Sanderson et al., 1996; Kropshofer et al., 1997), withoutdissociation was proportional to the intrinsic rate of dis-
sociation of a peptide for all peptide sequences and disrupting the overall structure of DR as judged by rec-
ognition by T cells (Guerra et al., 1998). The same lateraldifferent class II allelic molecules tested. This conserva-
tion across peptides and class II alleles suggested that surface is weakly implicated by the interference with
DM activity by molecules thought to bind to near thatsome of the bonds that are conserved in all peptide/
class II MHC interactions like those involving peptide surface: Cer-CLIP, an antibody to the N terminus of
CLIP (Denzin and Cresswell, 1995), and thesuperantigenmain chain atoms are the ones disrupted in the DM
catalyzed transition state (Weber et al., 1996) rather than TSST-1 (Kim et al., 1994).
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A testable although speculative model for DM cata- Table 1. Statistics for Data Collection and Refinement
lytic activity would be for a nonpolar residue like Trp
Data collection
a62 on this lateral face of DM to contact Phe a51 of DR,
Resolution (AÊ ) 34±2.5 2.59±2.5which projects off the surface of DR at the N-terminal
Unique reflections 18,729 1,837end of the extended strand characteristic of the ªleftº
Completeness (%) 96.2 96.3
end of the peptide-binding sites of class II molecules, Average I/s(I) 27.7 6.9
and to move neighboring Ser a53, breaking two con- Redundancy 7.3 7.0
served peptide-to-MHC hydrogen bonds (P-2 and P-1 Rsym (%) 5.5 21.3
in Figure 3). In such a hypothetical interaction, a polar
Refinement Results (34±2.5 AÊ )
residue like Asp a61 (Glu in mouse) of DM might contact
Reflections (free) 16,887(1,842)His b81 of DR, distorting a third conserved peptide-to-
Rcryst (Rfree) (%) 19.4(25.6)MHC hydrogen bond (P1 in Figure 3). Such a DM/DR
Non-hydrogen protein atoms 3,002
interaction could lower the free energy barrier to peptide Water molecules 198
dissociation and have the properties of an open transi- Carbohydrates 3(Asn a15)
tion state conformer of DR favoring faster peptide asso- R.m.s. deviations
Bonds (AÊ ) 0.008ciation as well. Mutations at DR His b81 or in the putative
Angles (8) 1.35DM/DR interface or the structure of DM/DR complex
B factors (AÊ 2) 3.5could test this model or, in the latter case, may suggest
Ramachandran Plot Statistics (%)another mode of destabilizing the peptide/DR interface.
Residues in most favored regions 89.8
Experimental Procedures Residues in additional allowed regions 9.6
Residues in generously allowed regions 0.6
Purification and Crystallization Residues in disallowed regions 0.0
DM, expressed and isolated as described previously (Sloan et al.,
I/s(I) is the mean reflection intensity/estimated error. Rsym 51995), was further purified by gel filtration (Superdex 200) and ion-
(S|I(i) 2 ,I.|)/SI(i), where I(i) is the intensityof an individual reflectionexchange chromatography (Mono-Q Sepharose, Pharmacia). Two
and ,I. is the average intensity of that reflection. Rcryst 5crystal forms were grownat 48C by combining 2 ml of protein solution
S||Fo|2|Fc||/S|Fo|, where Fo and Fc are the observed and calculated(20 mg ml21 in 10 mM TRIS [pH 8.0]) with 2 ml of precipitant (1 M
structure factor amplitudes. Rfree is equivalent to Rcryst, but calculatedLi2SO4, 0.5 M (NH4)2SO4, and 0.1 M sodium citrate [pH 5.4]). The
for a randomly chosen 10% of reflections that were omitted fromstructure was determined from an orthorhombic crystal, C2221, a 5
the refinement process.95.4 AÊ , b 5 109.9 AÊ , c 5 105.1 AÊ , with one molecule per asymmetric
unit. Diffraction data were collected from a single flash-cooled crys-
tal (100 K), using a Mar Research image plate detector and an
Elliot GX-13 rotating anode source with mirror optics. Data were lie in the allowed regions of the Ramachandran plot, with 90% in
integrated and scaled (Table 1) with DENZO and SCALEPACK (HKL the most favorable regions. Side chains of residues b139-145 exhib-
Research). Most of the subsequent processing used the CCP4 pro- ited weak electron density and B factors around 70 AÊ 2. Residues
grams (Collaborative Computational Project, 1994). An overall iso- a1-12, b1-2, and those from the C termini, including the epitope-tag
tropic B factor was 38 AÊ 2, with no evidence for anisotropy as esti- peptides, were not detected in the electron density maps, probably
mated from a Wilson plot. because of disordering.
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